Fibroblast growth factor receptor 4 (FGFR4) is expressed in 50 -70% of pancreatic carcinomas (PC) and a similar proportion of derived cell lines. Here we determine the sites of FGFR4 transcriptional initiation which show a pattern characteristic of genes with GCrich, TATA-less promoters. We have examined the chromatin structure around the FGFR4 gene in a panel of expressing and non-expressing PC lines using the DNase I hypersensitive site assay. One region of hypersensitivity, located largely within intron 1, was found to be greatly extended in expressing cells. Subsequent functional analyses using reporter assays demonstrated that this region was able to act as a cellspecific enhancer, only showing significant activity in PC lines expressing endogenous FGFR4. Transcription factors able to bind to the enhancer were investigated using footprinting and mobility shift assays and two binding sites for Sp1 proteins and two sites able to bind hepatic nuclear factor 1 (HNF1) proteins were identified. Further reporter assays using constructs mutated in each binding site demonstrated that HNF1 binding was essential for enhancer activity in expressing cells, an observation that correlated with the increased abundance of HNF1a in these same cells as measured by Western blotting. Finally we show that exogenous expression of HNF1 factors in an FGFR4 non-expressing line led to an induction of enhancer activity in reporter assays and also activated expression of the endogenous gene. We conclude that HNF1a is a major determinant of FGFR4 expression in PC.
Introduction
Despite having a relatively low incidence, pancreatic carcinoma (PC) is the fourth commonest cause of cancer-related death in the Western World. The late presentation of the disease, combined with the lack of effective treatment regimens, means that fewer than 5% of patients survive 5 years beyond diagnosis. These facts have led to multiple efforts to define the tumorigenic process in terms of the molecular events involved in order to identify new targets for novel therapies. Histopathologically, PC is an adenocarcinoma arising in the epithelial lining of the exocrine ductal system. Genes that have been shown to play a key role include the oncogene K-RAS and the tumour suppressor genes CDKN2 (p16), TP53 and DPC4 which encodes Smad4 and is part of the TGFb signalling pathway (reviewed in Kern, 2000) .
Several other growth factors and their receptors have also been implicated in pancreatic carcinogenesis including the fibroblast growth factors (FGFs) and their receptors (FGFRs) . There are to date 22 known FGFs (reviewed in Ornitz and Itoh, 2001 ) and four receptors, FGFR1, 2, 3 and 4 which all have the same basic structure and are members of the receptor tyrosine kinase family (reviewed in Johnson and Williams, 1993) . FGFR expression is strongly upregulated in a variety of tumours, most notably adenocarcinoma of the breast and pancreas. For example, 50 -70% of PC and a similar proportion of derived cell lines overexpress FGFR1, 3 or 4 (Kobrin et al., 1993; Leung et al., 1994; Ohata et al., 1995) . Increased expression of both FGFR2 and FGF7 has also been found in a high proportion of PC and this correlated with tumour stage, shorter post-operative survival and the presence of lymph node metastases (Ishiwata et al., 1998) . Thus FGFs/FGFRs may form part of an autocrine or paracrine loop helping to drive tumour proliferation and may possibly play an aetiological role. Expression of a dominant negative, kinase-deficient, truncated form of FGFR1 in a PC cell line resulted in attenuated tyrosine phosphorylation and a reduction in tumour forming potential in vivo (Wagner et al., 1998) . Somatic mutations in FGFR2 and FGFR3 have been documented in human colorectal, bladder and cervical malignancies (Cappellen et al., 1999; Jang et al., 2001 ) and accelerated tumour progression and increased cellular motility have recently been associated with a naturally occurring FGFR4 polymorphism in breast and colorectal patients (Bange et al., 2002) .
The involvement of FGF/FGFRs in pancreatic carcinogenesis is probably the result of the reexpression of genes originally active during embryonic life. The FGF signalling pathway is an intrinsic mediator of cell -cell communication in tissue remodelling in development and in cellular homeostasis in adult organs (Mason, 1994; McKeehan et al., 1998) . Thus the four receptor genes are expressed in development in a temporal and spatially specific manner (Xu et al., 1999) and in adult tissues in a cell type-specific manner (McKeehan et al., 1998) . The development of the exocrine pancreas, unlike the endocrine pancreas, depends on epithelial-mesenchymal interactions and it is these interactions that are thought to be mediated by FGF signalling, particularly via FGFR2 (Miralles et al., 1999) . The expression patterns of other family members also suggest a role: in mouse, fgfr1 and fgfr4 were shown to be expressed at a high level during early pancreatic organogenesis before embryonic day 16, their levels of expression decreasing thereafter. FGFs were also shown to be highly mitogenic for embryonic pancreatic epithelial cells (Le Bras et al., 1998) .
We were interested in examining how the FGFR4 gene becomes reactivated in a proportion of pancreatic tumours. No evidence for amplification or rearrangement of the gene in tumours or derived cell lines had been reported (Leung et al., 1994) , pointing at a deregulation of transcription being the underlying mechanism. Using a panel of PC lines, either expressing or not expressing FGFR4, we were able to map an intron 1 enhancer whose activity is required for FGFR4 gene activation. Further characterization led to the identification of the liver-enriched transcription factor HNF1a as the major determinant of enhancer activity in FGFR4 expressing pancreatic tumour lines.
Results

Localization of the FGFR4 sites of transcription initiation in PC cells
The genomic sequence of human FGFR4 shows that the first exon (which is non-coding) lies within an extensive CpG island and comparison with the sequence of the longest cDNA clone had allowed an approximate transcription start site to be assigned (Kostrzewa and Muller, 1998) . However, since sequences 5' of this suggested the gene was controlled by a TATA-less, GC-rich promoter which usually have multiple start sites, we began our study by accurately mapping the transcription initiation site(s) used in PC cells. For these and subsequent experiments we used a panel of PC lines which were shown by Northern blotting (Leung et al., 1994;  Figure 1 ) to either significantly express FGFR4 (HPAF, CFPac1 and ASPC1) or have little or no expression of this gene (Panc1, T3M4 and BxPC3).
We designed an *265 kb antisense riboprobe spanning the start of the 1st exon (see Materials and methods), as depicted in the diagram in Figure 2 . This was used in an RNase protection assay with RNA prepared from FGFR4 expressing and non-expressing A rhabdomyosarcoma cell line (RD; lane 10) and the cervical carcinoma line HeLa (lane 9) acted as positive and negative FGFR4 expression controls respectively (Armstrong et al., 1992) . Labelled MW markers (sizes shown in bp) were run in lane 2 and a sequencing reaction using a primer to the 3' end of the riboprobe in lanes 11 -14. The base designated in this study as +1 is indicated by the arrow tion initiation in each of the FGFR4 expressing cell lines (HPAF, CFPac1 and ASPC1). The corresponding bases were identified from the accompanying sequencing reaction (see Materials and methods). Two major groups of start sites were observed plus several minor ones, the pattern being the same for all the FGFR4 expressing lines. The major downstream site was designated as +1 and lies within the sequence CATT(+1)CC.
Identification of potential sites of transcriptional regulation within the FGFR4 gene in PC cells
Although the promoter is required for defining the transcription start site(s) of a gene, it does not always represent the major determinant of the cell-specific expression pattern. Enhancer/silencer regions that may lie many kilobases 5' or 3' of +1 are often found to provide key additional transcriptional regulatory sequences. We therefore used the DNase I hypersensitive site (HSS) assay to probe the chromatin structure around the endogenous FGFR4 gene in PC cells; by comparing the sensitivity patterns in expressing and non-expressing cells it was hoped that the location of potential regulatory sequences would be identified. Initially we looked for hypersensitive sites within the 8 kb EcoRI fragment that spans -1140 to + 6900 of FGFR4 (see diagram, Figure 3 ). The DNA samples from each cell line in turn were digested with EcoRI, blotted and probed with a genomic AccI -AccI fragment ( -375 to -931; see Figure 3 ). In autoradiographs from these experiments (data not shown) the full-length 8 kb genomic EcoRI fragment was seen to disappear gradually with increasing DNase I digestion while several bands of lower molecular weight were seen to appear. An optimally DNase I digested sample from each cell line was selected and the restriction digest and blotting were repeated on these samples to allow direct comparison of FGFR4 expressing and non-expressing cells (Figure 3 ). The size of the lower MW bands allowed the location of three hypersensitive sites to be mapped to regions I, II and III within the FGFR4 gene. Hypersensitive sites I and II were present in all six cell lines and mapped to the presumed promoter region immediately 5' of the transcription start site. The third region of hypersensitivity, III, was found in FGFR4 expressing cell lines and mapped to an extended region encompassing parts of the first exon and first intron. In FGFR4 non-expressers this region of hypersensitivity was much more compact and was confined to the 5' end of the domain mapped in expressing lines (Figure 3 , compare lanes 8, 10 and 12 with 2, 4 and 6). This suggested that region III may play a functional role in controlling the cell-specific expression of FGFR4.
Further DNase HSS mapping was performed using different probes with a variety of genomic digests which allowed us to screen the gene from -11 to +13.6 kb. No further hypersensitive sites were found (data not shown).
A genomic fragment containing the intron 1 region of hypersensitivity functions as a cell-specific enhancer
The functional activity of the DNase I hypersensitive regions was assessed using reporter constructs in shortterm transfection assays in FGFR4 expressing and nonexpressing PC lines. Initially, promoter activity (hypersensitive sites I and II) was examined using a series of constructs in pCATbasic containing different extents of FGFR4 5' flanking sequence (to -1140, -374, -174 and -61 ) but all with the 3' end at the EagI site at position +10 (see diagram, Figure 4 ). Transfection assays were performed in two FGFR4 expressing lines (HPAF and ASPC1) and two non-expressers (Panc1 and T3M4) and increases of 5 -75-fold over pCATbasic activity were observed in the four cell lines, thus confirming that these sequences possess promoter activity ( Figure 4 ). The smallest promoter construct used (to the ApaI site at -61; pminPCAT) showed the lowest level of CAT activity in all four cell lines (5 -8-fold over pCATbasic; Figure 4 ). However, overall the relative levels of promoter activity did not reflect the pattern of FGFR4 mRNA expression (shown in Figure  1 ): ASPC1 and Panc1 gave 20 -75-fold activation while HPAF and T3M4 showed 5 -20-fold activation. We concluded therefore that, as monitored by this assay, the proximal promoter region did not contain the major determinants of the cell-specific expression pattern of FGFR4 in PC lines.
The final region of DNase hypersensitivity we had found, site III in the first intron, was tested for potential enhancer activity by sub-cloning the encompassing genomic NgoMI -NgoMI fragment (+62 to +506) into the pCATbasic construct, pminPCAT, containing the FGFR4 minimal ( -61 to +10) promoter. As shown in Figure 5 (columns +enh), this region was found to enhance CAT expression over 30-fold in the FGFR4 expressing line, HPAF, without significantly affecting activity in FGFR4 non-expressing Panc1 cells. This cell line-specific enhancer activity was also observed on transfection of T3M4 and ASPC1 cells (data not shown) and when the same fragment was used in conjunction with the heterologous minimal SV40 promoter ( Figure 6 ). Fragments containing longer regions of the FGFR4 first intron (up to 150 bp of additional 3' sequence) did not show any further enhancement of activity in these assays (data not shown). In both contexts, activity was observed independent of orientation (Figures 5 and 6) , therefore these data demonstrate that the NgoMI -NgoMI fragment can operate as a classical cell line specific enhancer for FGFR4 transcription.
Sp1 and HNF1 bind to the FGFR4 enhancer in PC cells
Enhancers work by recruiting specific DNA binding transcription factors, which in turn interact directly or indirectly with the transcription initiation complex forming at the promoter to influence the level of gene expression. In order to identify the factors required for enhancer activity in PC cell lines, we performed in vitro HNF1a up-regulates FGFR4 expression in pancreatic cancer RNH Shah et al DNase I footprinting using the NgoMI -NgoMI fragment as the probe. This was incubated with crude nuclear extracts from HPAF cells prior to limited DNase I treatment. The resulting fragments were resolved on sequencing gels. As shown in Figure 7 , four protected regions (A, B, C and D) were identified; the diagram indicates their relative positions across the enhancer.
By comparing the protected regions with the sequencing lane on the same gel, the sequences bound by each of the four footprints could be determined and these were used to generate oligonucleotides (see Materials and methods for sequences) to use as probes in electromobility shift (EMSA) assays. We were able to demonstrate specific retardation and hence specific transcription factor binding with each of the four probes (FpA, FpB, FpC and FpD): each retarded band was competed by its own, unlabelled binding site (complexes indicated with an arrow in Figure 8a , lanes 1 -3; Figure 8b , lanes 1 -3; Figure  8c , lanes 1 -3 and 9 -11) while mutant sequences (see Materials and methods for sequences) failed to compete (Figure 8a, lanes 6, 7; Figure 8b, lanes 6, 7; Figure 8c, lanes 6, 7 and 14, 15) . Each probe also produced a number of non-specific complexes (indicated by asterisks, Figure 8 ); these were not reproducibly competed by the wild-type sequence and were not therefore analysed further. Figure 3 DNase HSS assay on six PC cell lines. Genomic DNA from each cell line (FGFR4 expressers, lanes 1 -6; non-expressers lanes 7 -12) was digested with EcoRI, blotted and probed with the FGFR4 genomic AccI -AccI fragment (see line drawing). For each cell line two lanes are shown, one using genomic DNA untreated with DNase I ( -) and the other genomic DNA from nuclei that had been treated with DNase I prior to DNA recovery (+). The parent 8 kb fragment can be seen in each lane. Several faster migrating bands appear with DNase I exposure and the position of three major hypersensitive sites I, II and III relative to the genomic structure is shown on the line drawing. The band of *1.5 kb in lane 11 is due to contaminating plasmid sequences in this sample
The similar migration of the specific complexes bound to FpA and FpB indicated that the same factor(s) could interact with these two sites. This was confirmed by cross-competition analysis which showed that FpB could compete FpA binding and vice versa ( Figure  8a ,b lanes 4 and 5) although FpB is clearly the higher affinity site. Similarly, FpC and FpD could be shown to bind similar factors by cross-competition (Figure 8c , lanes 4, 5, 12 and 13). Analysis of the footprinted sequences using Web-based software (see Materials and methods) suggested a number of factors as cognate binding proteins for each of the four sites. Oligonucleotides to known binding sites for the suggested factors were used in further competition assays (data not shown) and these showed that footprints C and D were bound by Sp1 while footprints A and B were both bound by hepatocyte nuclear factor I (HNF1) proteins. A comparison of the consensus binding sites for these factors with the core binding sequence in each footprint is shown in Figure 9a . The fact that the FpB sequence more closely resembles the HNF1 consensus site probably explains why it is the higher affinity site of the two. These binding site assignments was confirmed by the use of specific antibodies in supershifting EMSA (Figure 8a and b, lane 8 for HNF1 and Figure 8c , lanes 8 and 16 for Sp1). The interaction that remains after challenge with Sp1 antibodies is due to the binding of the highly related Sp3 factor which is present at low levels in all the PC lines (data not shown). The FGFR4 enhancer can act on a heterologous promoter. Reporter constructs based on pCATpromoter (pCATP) were made containing the FGFR4 intronic enhancer (pCATP+enh) cloned in either orientation (ori1 and ori2) and transfected into FGFR4 expressing (HPAF) and non-expressing (Panc1) cells. CAT activity relative to pCATP activity (set at 1) in the same cell line was calculated HNF1a binding is essential for FGFR4 enhancer activity in overexpressing PC cells A functional assessment of the importance of each binding site (A -D) to overall enhancer activity was made by using site-directed mutagenesis to create 4 -5 bp mutations within each binding site in turn which would abrogate factor binding, as previously demonstrated by EMSA (see Materials and methods and Figure 8 ). Mutations were made within the pCAT Promoter construct containing the full length wild-type enhancer ( Figure 6 ) and the activity of each mutant reporter construct was tested in further transfection assays in the FGFR4 positive line, HPAF. As shown in Figure 9b , mutation within either of the Sp1 binding sites (mutC and mutD) had little effect on enhancer activity. Mutation within either of the HNF1 binding sites, however, had a profound effect on enhancer activity with only 20 -30% of the activity of the wildtype enhancer being retained by either mutA or mutB and a reduction to 10% activity for the mutAB double mutant.
Since HNF1 binding to the FGFR4 enhancer was essential for its activity, we sought to find differences in abundance or activity of this factor in expressing and non-expressing cells that might account for the differential activity of the enhancer. The HNF1 family of transcription factors consists of two members, HNF1a (initially called LF-B1; Frain et al., 1989) and HNF1b (initially termed LF-B3 or vHNF1; de Simeone et al., 1991; Rey-Campos et al., 1991) which are encoded by distinct but homologous genes of the homeodomain super family. Western blotting of crude nuclear extracts was used to determine the relative abundance of these two proteins in our panel of PC lines while extract from HepG2 cells, known to express both proteins, was used as a positive control. All the lines showed a very low level of HNF1b expression (Figure 10b, 60 kDa band) . In contrast, the HNF1a expression profile exactly mirrored that for FGFR4 with all three expressing lines showing high levels of the factor while the non-expressing lines had barely detectable levels by Western blotting (Figure 10a , 80 kDa band, compare lanes 1 -3 with lanes 4 -6). For comparison, we also examined Sp1 levels in the same panel of lines. There was some variation in factor levels across the lines but in general Sp1 abundance was much more uniform and did not show any correlation with FGFR4 expression status (Figure 10c) .
The simplest explanation for the differential activity of the FGFR4 enhancer in the two PC phenotypes therefore is that the increased abundance of HNF1a in expressing cells leads to increased binding site occupancy and more efficient transcription initiation in these cells. To test this we wanted to determine if enhancer activity could be activated in non-expressing cells if these were engineered to overexpress HNF1. To this end we attempted to raise stable cell lines exogenously expressing either HNF1a or HNF1b. After screening a number of stable clones (see Materials and methods) we identified Panc1-derived lines that expressed elevated levels of either HNF1a (P1A.5 and P1A.6) or HNF1b (P1B.2 and P1B.5). As a control, we used Panc1 cells stably transfected with the parent expression vector (PC1). These lines, together with parental Panc1 cells, were transfected with three constructs: pminPCAT (containing the FGFR4 minimal promoter), pminPCAT+enhancer and pCATbasic to allow reporter activity to be compared across the six lines. These data are shown in Figure 11a . In Panc1 cells the presence of the FGFR4 enhancer had no significant effect on reporter activity as shown above (see Figure 5 ) and this was also observed with the control line, PC1. In contrast, in all four HNF1 expressing lines, the presence of the enhancer significantly increased reporter activity to 14 -19-fold over pCATbasic, which compares well with the levels of activity seen with the same construct in FGFR4 and HNF1a over expressing HPAF cells (see Figure 5) .
The series of stable cell lines was also examined for activity of the endogenous FGFR4 gene by Northern blotting. As shown in Figure 11b , while the parental Panc1 and control PC1 cells failed to show detectable FGFR4 expression, all four lines exogenously expressing HNF1 now efficiently transcribe their endogenous FGFR4 gene, confirming the functional link between HNF1 and FGFR4 expression in PC. 
Discussion
At the start of this study we mapped the FGFR4 transcription start sites and defined the proximal gene promoter used in a panel of pancreatic carcinoma lines. The pattern of degeneracy in the site of transcription initiation is characteristic of TATA-less, GC-rich promoters. We nominated the major downstream start site as +1 and this agrees well with other published studies, being 14 bp 5' of the longest FGFR4 cDNA clone (Kostrzewa and Muller, 1998) and 2 bp 3' of the start site identified using RNA from the human liver carcinoma line, Hep3B (Becker et al., 2000) . We were not able to detect any major determinants of cellspecific expression within the FGFR4 proximal promoter. As the promoter lies within a CpG island it is possible that differential methylation may play a role in transcriptional regulation. However, unmethylated, cloned reporter constructs did not demonstrate universally high activity in all cell lines as might be expected (Kudo and Fukuda, 1995) were this a major regulatory mechanism for FGFR4 expression in PC. Although we have not examined this in detail it is likely that the FGFR4 promoter activity may rely on the binding of Sp1 factors as 6 -7 potential binding sites lie in the immediate vicinity of +1 (Becker et al., 2000) . The proximal promoters of FGFR1 (Parakati and DiMario, 2002) and FGFR3 (McEwen and Ornitz, 1998) also lie within CpG islands and have been shown to be dependent on Sp1-related factors for activity.
As the aim of our study was to identify the mechanism whereby a proportion of PC lines and tumours overexpress FGFR4, we used the DNase I hypersensitive site assay to search for differential 16) , with no competitor (lane 9), or 20-and 100-fold excess of FpD competitor (lanes 10 -11); FpC (lanes 12 -13); MutD oligo (lanes 14 -15). Lane 16: as lane 9 plus 1 ml Sp1 antibody. Only the DNA/protein complexes are shown; *Non-specific complexes regulatory regions. A major finding of this study is that the presence in all expressing lines of a region of extended hypersensitivity within the first intron of the endogenous FGFR4 gene (site III, Figure 3 ) correlated with the subsequent data showing that this region can act as an enhancer in the same cell lines in short term reporter assays (Figures 5 and 6) . Furthermore, the activity of the enhancer was shown to be dependent on the integrity of the two HNF1 binding sites found within it (Figure 9 ) which in turn correlated with the expression profile, particularly for HNF1a, within the PC lines as determined by Western blotting (Figure 10 ). Our data in Figure 11 complete the functional link between FGFR4 enhancer activity and HNF1 expression in PC by showing that forced expression of either isoform in low expressing cells can activate the enhancer, not only in reporter assays but also by acting on the endogenous gene. Our data do not totally exclude the possibility that HNF1a may also act in an indirect manner on the FGFR4 gene but the balance of evidence points to a direct regulatory role.
The fact that both HNF1 isoforms can activate the enhancer (Figure 11) is not surprising as HNF1a and b have identical DNA binding specificities (Frain et al., 1989) . The increase in enhancer-mediated reporter activity observed with the HNF1 expressing stable lines was not quite equivalent to the fold induction seen in HPAF cells, but the fact that all four lines showed the same trend is compelling. It is also possible that the Panc1 low expressing cells lack other cofactors required for optimal HNF1 activity. Recent reports have shown that HNF1a exerts its transactivation functions by interacting with, and thus activating, a number of histone acetyltransferases (HATs) including CBP/p300, pCAF and SRC1 (Soutoglou et al., 2000 (Soutoglou et al., , 2001 . Western blotting showed that all the PC lines express most of these proteins (our unpublished results) but, as haploinsufficiency of many of these factors can compromise function, it is possible that these levels are insufficient for maximal HNF1 activity, particularly for reporter assays where saturating levels of plasmid are often an issue. Clearly though, the expression of HNF1a or b alone is sufficient to activate expression of the endogenous FGFR4 gene as shown in Figure  11b .
The correlation between FGFR4 expression and HNF1a is very tight in our panel of PC lines and some comparison can also be made between in vivo expression patterns of HNF1 family members and FGFR4. Becker et al. (2000) examined the levels of FGFR4 mRNA in normal adult human tissue using Northern blotting and showed expression in adult human lung, liver, kidney and pancreas. Much lower levels of expression were seen in skeletal muscle, heart and placenta while no expression was seen in brain Figure 9 The HNF1a sites within the enhancer are required for its activity. (a) Consensus binding sites for HNF1 (Frain et al., 1989) and Sp1 (Suske, 1999) are shown compared to the core binding sequences of each relevant footprint. Identity with the consensus is indicated in bold. (b) Site directed mutagenesis was used to create a series of mutants in the pCATP+enh background (see Figure 6 ) whereby factor binding at each footprint site in turn was abolished (see Materials and methods). The wild-type and mutant reporter constructs were transfected into HPAF cells and CAT activity relative to the activity of the wild-type enhancer, set at 100%, is shown tissue. Immunohistochemical techniques demonstrate that pancreatic expression occurs within the islets of Langerhans (Hughes, 1997) . This expression profile compares well with that for HNF1: HNF1a is expressed in adult liver, kidney, gut and pancreas (Frain et al., 1989) ; HNF1b is also expressed in the lung (Coffinier et al., 1999) . It is possible therefore that the intronic enhancer may also regulate FGFR4 expression in other tissues in addition to the pancreas. In the only other report looking at FGFR4 gene regulation, Becker et al. (2000) describe differential reporter activity between Hela (FGFR4 negative) and Hep3B (FGFR4 expressing) cells. This was attributed to promoter activity but, the 3' end of their reporter constructs mapped within the second exon and consequently contained the whole first intron in addition to the promoter. We contend therefore that these workers too were observing the effect of the intron 1 enhancer identified here, particularly as HNF1 factors are also abundant in Hep3B cells.
In mouse, HNF1b is expressed in the exocrine ducts of the adult pancreas (Coffinier et al., 1999) but pancreatic expression of HNF1a is confined to the beta cells of the islets where it is required for the expression of genes involved in the insulin secretory response (reviewed in Ryffel, 2001) . Thus the expression of HNF1a in PC, which is thought to arise in the exocrine ducts, is unexpected. HNF1 factors have been most studied in the context of hepatic differentiation. Together with a number of other liver-enriched factors they are involved in a complex cross-regulatory network whereby synergistic interactions serve to regulate the expression not only of target genes but also the transcription factors themselves (reviewed in Cereghini, 1996) . In this context, the main regulator of HNF1a is thought to be the unrelated HNF4a (Li et al., 2000) but this factor is not significantly expressed in the adult exocrine pancreas either. More recently, another possible regulator of HNF1a has been suggested. The fetoprotein transcription factor (FTF; also called LRH-1) is a monomeric orphan nuclear receptor that seems to lie 'upstream' of HNF4a in liver differentiation. Functional FTF binding sites have been identified within the HNF1a proximal promoter and this factor is also expressed in the adult exocrine pancreas (Pare et al., 2001) . However, FTF activity appears to be limited to dividing cells. Thus in the normal adult pancreas FTF may not significantly activate HNF1a expression but during the tumorigenic process this pathway may become reactivated leading to increased FGFR4 expression. Further examination of both PC-derived cell lines and tumour samples will examine this possibility.
Materials and methods
Starting materials
Cosmids containing the entire genomic sequence of FGFR4 (Armstrong et al., 1992) , PC cell lines and the cDNA clone of the extracellular domain of FGFR4 (Leung et al., 1994) have been described previously. All cell lines were grown in RPMI 1640 with 10% fetal calf serum (FCS). Mammalian expression plasmids for HNF1a and HNF1b in pcDNA3.1 (Invitrogen) were provided by S Isshiki.
Northern blotting and RNase protection
Total cellular RNA was prepared from sub-confluent cells using TRIzol TM B (Gibco -BRL). For Northern blotting, samples (10 mg/lane) were separated on MOPS/formaldehyde gels and capillary blotted to Hybond N + membrane. Parallel samples were stained with ethidium bromide to assess the 28S:18S ratio to verify RNA integrity. Probes were labelled by random priming and blots were hybridized using standard techniques (Ausubel et al., 1994) . For RNAse protection, the XhoI -BpmI genomic restriction fragment ( -175 to +87) was sub-cloned into pBluescript (Stratagene) and linearized at the 5' side of the insert to generate a template for probe preparation. An a 32 P-UTP-labelled antisense riboprobe was generated using an in vitro transcription kit with T3 Figure 11 Exogenous expression of HNF1 in non-expressing cells activates the FGFR4 enhancer and the endogenous gene. (a) Stable cell lines were derived from the Panc1 FGFR4 non-expressing line (see Materials and methods). Panc1 and PC1 have low levels of HNF1 proteins. P1A.5 and P1A.6 overexpress HNF1a; P1B.2 and P1B.5 overexpress HNF1b. The reporter constructs pCATbasic (pCATb), pminPCAT containing the minimal FGFR4 promoter ( -61 bp +10) and pminPCAT+enh were transfected into each of the six lines and CAT activity was normalized to pCATb activity (set at 1) in the same line to allow relative reporter activity to be compared between the lines. (b) Total RNA was isolated from the control (Panc1 and PC1) and HNF1 overexpressing stable lines described above and assayed for FGFR4 transcript levels by Northern blotting (see Figure 1 ). FGFR4 expressing (ASPC1) and non-expressing (BxPC3) cells were run as additional positive and negative controls as indicated. The blot was reprobed for GAPDH to control for loading polymerase (Promega) and gel purified. RNase protection assays were performed using the RPA II TM kit (Ambion) according to the manufacturer's instructions. Total cellular RNA (25 g) were incubated with the riboprobe (5610 5 c.p.m. per sample). Hybridization was performed overnight at 558C, followed by RNaseA/RNaseT1 digestion at 378C for 1 h and the resultant fragments were resolved on a 6% denaturing gel. A sequencing reaction, using a primer to the 3' end of the insert, was used to estimate the position of transcription start sites after correction for the differential gel migration of RNA and DNA species (Ausubel et al., 1994) .
DNaseI hypersensitive site assay
Nuclei were isolated from PC cell lines by detergent lysis of the cell membrane. Aliquots were incubated with DNase I (Worthington) at concentrations of 0 to 100 mg/ml for 10 min at 378C. Genomic DNA was purified by proteinase K digestion, phenol/chloroform extraction and ethanol precipitation. Hypersensitive sites were demonstrated by Southern blotting of restricted DNA and hybridization with radiolabelled genomic probes. The size of each band was determined by comparison of its electrophoretic mobility with that of standard markers (1 kb ladder, Life Technologies).
Transfection assays
Reporter constructs were initially made in pCATbasic (Promega) as shown in Figures 4 and 5. Enhancer activity was also investigated using pCATpromoter (Promega) which contains the minimal SV40 promoter (see Figure 6 ). PC cells are notoriously difficult to transfect. After optimization we were able to transfect Panc1 cells with Lipofectin (Life Technologies) to an efficiency of *30%, HPAF and T3M4 cells were transfected with Fugene 6 (Boehringer Mannheim) to an efficiency of *10% and *5% respectively and ASPC1 cells were transfected with Lipotaxi (Stratagene) to *5% efficiency. Cells were split to be 20 -30% confluent on the day of transfection and were harvested after 72 h. The b-gal expression vector, pCH110 (Pharmacia) was co-transfected to control for transfection efficiency. After harvesting, cell lysates were analysed for b-gal and CAT activity using standard techniques (Ausubel et al., 1994) . All experiments were performed in duplicate and repeated at least three times to allow the calculation of standard deviations of the mean, which are displayed as error bars.
DNase I footprinting
The NgoMI -NgoMI enhancer fragment was cloned into pBluescript (Stratagene), re-excised and end-labelled with a 32 P-dATP at either the 5' or 3' end. End-labelled probe (7 fmol) was incubated with crude nuclear extract (Dignam et al., 1983) followed by partial DNase I treatment, proteinase K digestion, phenol/chloroform extraction and ethanol precipitation before fragments were resolved on a denaturing polyacrylamide gel. Additional lanes were loaded with an A+G chemical degradation sequencing ladder generated from the same probe and a control DNase I digest of probe that had not been pre-incubated with nuclear extract.
Electromobility shift assays (EMSA), oligonucleotides and mutagenesis
EMSAs were performed with end-labelled double stranded (ds) oligonucleotides corresponding to each of the four protected footprint regions as probes as previously described (Bosher et al., 1995) . The following sequences were used: FpA= GGGGCGGTAAATCAGtaaccCGCAGTGCACACAGG; FpB=CTggttACTCATTGCCCACCGAGGCG; FpC= CCCATTGATTCGCACctccCCCCAGGCTGG; FpD=AG-CCAGGTGAggagGAGCCAGGTGAGC. Potential factors binding to these sites were predicted using Matinspector (http://genomatix.gsf.de/mat_fam). Core binding sites for HNF1 (FpA and FpB) and Sp1 (FpC and FpD) are shown in bold type. Mutant oligonucleotides to each of the footprinted regions were tested in EMSA to ensure they were unable to compete with the wild-type sequence (Figure 8 ) and were unable to bind other factors (data not shown). The lower case bases in the sequences above were mutated to the following: FpA=GTGTG (mutA), FpB=CACA (mutB), FpC=TTTT (mutC) and FpD=TCAC (mutD). These same mutations were also introduced into the full length enhancer within the pCATP+enh construct using a site-directed mutagenesis kit (Quickchange, Stratagene). MutAB is mutated at both sites A and B. Supershifting experiments were performed by incubation of crude nuclear extract with the relevant antibody (pan HNF1 antibody H205 or Sp1 antibody PEP2, Santa Cruz, CA, USA) for 1 h at 48C prior to addition of the probe. Competition experiments were performed with 20-and 100-fold mass excess over the labelled probe.
Western blotting
Nuclear extract (10 g) was separated by SDS -PAGE together with Full Range MW markers (Amersham). Gel transfers to Hybond-ECL nitrocellulose (Amersham-Pharmacia) and primary and secondary antibody incubations were performed using standard techniques. The chemiluminescent detection of horseradish peroxidase-conjugated secondary antibodies was performed using the West Femto Maximum Sensitivity Substrate kit (Pierce) according to the manufacturer's instructions. Primary antibodies to HNF1a and HNF1b (C19 and C20, Santa Cruz, CA, USA) were diluted one in 200 prior to incubation with the blot for 2 h at RT. The Sp1 primary antibody (PEP2, Santa Cruz, CA, USA) was diluted 1 : 1000 prior to incubation. To reprobe for normalization, membranes were stripped in 2% SDS, 62.5 mM Tris-HCl, pH 6.7, 100 mM b-mercaptoethanol for 30 min at 558C and then reblocked prior to incubation with the goat polyclonal Ku-70 antibody (C-19, Santa Cruz, CA, USA).
Stable cell lines
Stable cell lines expressing either HNF1a or HNF1b were generated by transfecting Panc1 cells with 0.5 mg of linearized expression plasmid and selection in medium containing 1 mg/ ml G418 (Life Technologies). Resistant colonies were isolated, expanded and examined for expression of HNF1 proteins by Western blotting of whole cell extracts (data not shown). Appropriate lines were used in short term transfection assays as detailed above for the parental line. The PC1 control line was derived by transfection with the parent pcDNA3.1 vector.
